New BARDA Award: Immunexpress Inc. null Product
Post# of 36537
(Total Views: 433)
Posted On: 06/16/2020 9:49:34 AM
New BARDA Award: Immunexpress Inc. null
Product Name: SeptiCyte RAPID Host-Based Sepsis In Vitro Diagnostic
View Announcement
Description:
SeptiCyte® RAPID is a host response gene expression, blood-based diagnostic for rapid identification of sepsis that will be evaluated to triage COVID-19 patients for severe outcomes (sepsis) in the ICU and ED. Septicyte Rapid is currently seeking 510(k) clearance but will be further validated for use for COVID-19 patients with viral sepsis.
Unique Impact:
A diagnostic tool, such as SeptiCyte RAPID, can aid in triaging COVID-19 for severe disease outcomes, sepsis. This can assist healthcare providers in determining which patients as identified in the ED and ICU need escalated care for earlier clinical intervention to improve patient outcomes as well as aid in allocating resources.
Award Amount: $599,549.00
Product Name: SeptiCyte RAPID Host-Based Sepsis In Vitro Diagnostic
View Announcement
Description:
SeptiCyte® RAPID is a host response gene expression, blood-based diagnostic for rapid identification of sepsis that will be evaluated to triage COVID-19 patients for severe outcomes (sepsis) in the ICU and ED. Septicyte Rapid is currently seeking 510(k) clearance but will be further validated for use for COVID-19 patients with viral sepsis.
Unique Impact:
A diagnostic tool, such as SeptiCyte RAPID, can aid in triaging COVID-19 for severe disease outcomes, sepsis. This can assist healthcare providers in determining which patients as identified in the ED and ICU need escalated care for earlier clinical intervention to improve patient outcomes as well as aid in allocating resources.
Award Amount: $599,549.00
(0)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼